New hope for bile duct cancer: experimental drug faces final test
NCT ID NCT07582315
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 538 people with advanced biliary tract cancer that has worsened after prior treatments. The goal is to see if the new drug helps people live longer. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug given by IV infusion every 3 weeks)
What this could lead to
If successful, this could provide a new treatment option for people with advanced biliary tract cancer who have run out of standard therapies.
What could go wrong
This is an early Phase 3 trial, so results are not guaranteed. The new drug may not improve survival or could have side effects that outweigh benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact